Hepatology
Conference Coverage
Treatment of HCV in special populations
MAUI, HAWAII – Acute hepatitis C infection sometimes warrants treatment.
Conference Coverage
New options emerge for primary biliary cholangitis
LAS VEGAS – Fibrates and other peroxisome proliferator-activated receptor agonists are emerging.
Conference Coverage
Hep B therapy: Indefinite or FINITE for e-negative patients?
LAS VEGAS –
Conference Coverage
DAAs open up organ donation from HCV patients
No sign of viral infection.
From the Journals
VIDEO: Pioglitazone benefited NASH patients with and without T2DM
Has NASH met its match?
Daily News Podcast
MDedge Daily News: Can androgen therapy improve male frailty?
And empagliflozin could cut liver fat in diabetes.
Conference Coverage
MicroRNAs flag liver damage in HIV-, HCV-infected persons
MicroRNAs are associated with elevated liver enzymes and fibrosis in HIV, HCV infection.
Conference Coverage
Switching to tenofovir alafenamide may benefit HBV patients
PHILADELPHIA – It has similar efficacy to tenofovir disoproxil, with fewer bone and renal effects, according to results of two large international...
Conference Coverage
Pre-screening could help identify NAFLD biopsy candidates
PHILADELPHIA – Metabolic syndrome and liver stiffness measured by VCTE or MRE are among the criteria that can be used for at-risk patients.
From the Journals
Tenofovir didn’t prevent hepatitis B transmission to newborns
The maternal HBV transmission rate was unexpectedly low in both the placebo and active groups.
From the Journals
NASH rapidly overtaking hepatitis C as cause of liver cancer
The analysis is based on National Health and Nutrition Examination Survey and the Organ Procurement and Transplantation Network data.